Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study

溃疡性结肠炎 医学 内科学 选择(遗传算法) 结肠炎 胃肠病学 计算机科学 人工智能 疾病
作者
Edward V Loftus,Séverine Vermeire,Brian G Feagan,Franck-Olivier Le Brun,Alessandra Oortwijn,Ulrik Moerch,William J Sandborn,Toshifumi Hibi
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
标识
DOI:10.1093/ecco-jcc/jjac122
摘要

Abstract Background and Aims Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderately to severely active UC. Methods These post hoc analyses assessed 1-, 3-, 6-, and 8-month rates of corticosteroid-free clinical remission at Week 58 and change in median daily prednisone-equivalent dose over time. A matching-adjusted indirect comparison [MAIC] of maintenance studies assessed corticosteroid-free remission with filgotinib 200 mg, intravenous vedolizumab, subcutaneous vedolizumab, and oral tofacitinib. Results The Maintenance Study full analysis set included 199 patients receiving filgotinib 200 mg and 98 receiving placebo. Among patients receiving corticosteroids at Maintenance Study baseline, at Week 58, 30.4%, 29.3%, 27.2%, and 21.7% receiving filgotinib had been in corticosteroid-free remission for ≥1, ≥3, ≥6, or ≥8 months, respectively, versus 6.4% receiving placebo across thresholds [p <0.05]. Median daily prednisone-equivalent dose decreased from 17.5 mg/day to 10.0 mg/day with filgotinib treatment during the Maintenance Study. Based upon the MAIC, filgotinib was associated with greater likelihood of corticosteroid-free clinical remission versus intravenous vedolizumab (odds ratio [OR], 15.2; 95% confidence interval [CI], 1.6–139.9; p <0.05]) and similar odds to subcutaneous vedolizumab [OR, 3.8; CI, 0.2–63.8; p = 0.36] in biologic-naïve patients, and similar odds to tofacitinib overall [OR, 2.0; 0.4–9.1; p = 0.39]. Conclusions Filgotinib 200 mg demonstrated corticosteroid-sparing effects and maintained corticosteroid-free clinical remission in patients with UC. MAIC results should be interpreted cautiously given the large CIs and differences in study design and patient populations. [ClinicalTrials.gov: NCT02914522].

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yyybxqmz发布了新的文献求助10
2秒前
JamesPei应助MOJITO采纳,获得10
4秒前
4秒前
cst完成签到,获得积分10
4秒前
loey完成签到,获得积分10
7秒前
量子星尘发布了新的文献求助10
7秒前
雨中尘埃发布了新的文献求助10
8秒前
科研通AI2S应助欧阳正义采纳,获得10
8秒前
8秒前
ll应助欧阳正义采纳,获得10
8秒前
9秒前
9秒前
勤恳化蛹完成签到 ,获得积分10
9秒前
Leo完成签到,获得积分10
11秒前
小鲸鱼发布了新的文献求助10
11秒前
英姑应助专注的明轩采纳,获得10
11秒前
12秒前
PengHu发布了新的文献求助10
12秒前
无心的迎荷完成签到,获得积分10
13秒前
满意溪流完成签到 ,获得积分10
13秒前
14秒前
方法完成签到,获得积分10
14秒前
慕青应助柏康娜采纳,获得10
14秒前
王梦豪发布了新的文献求助10
15秒前
lslfreedom发布了新的文献求助10
15秒前
呜呜完成签到 ,获得积分10
16秒前
17秒前
栗悟饭完成签到,获得积分10
17秒前
18秒前
小鲸鱼完成签到,获得积分10
18秒前
墨菲特发布了新的文献求助10
18秒前
20秒前
宁羽发布了新的文献求助10
22秒前
22秒前
23秒前
Garra9822发布了新的文献求助10
23秒前
same完成签到,获得积分10
23秒前
23秒前
huiyuan完成签到,获得积分10
24秒前
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970062
求助须知:如何正确求助?哪些是违规求助? 3514782
关于积分的说明 11175968
捐赠科研通 3250119
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804951